Global CAR T-Cell Therapy Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch＇s in-depth investigation and research, the global CAR T-Cell Therapy market size will reach 7,381.95 Million USD in 2025 and is projected to reach 34,749 Million USD by 2032, with a CAGR of 24.77% (2025-2032). Notably, the China CAR T-Cell Therapy market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
CAR T-cell therapy, or Chimeric Antigen Receptor T-cell therapy, is an innovative immunotherapy approach used to treat certain types of cancer, particularly blood cancers like leukemia and lymphoma. In CAR T-cell therapy, a patient＇s own T cells (a type of immune cell) are collected from their blood and then genetically engineered to express a chimeric antigen receptor (CAR) on their surface. This receptor is designed to recognize and target a specific protein found on the cancer cells. Once the CAR T cells are modified, they are multiplied in the laboratory and then infused back into the patient＇s bloodstream. These engineered T cells can now identify and attack cancer cells, effectively enhancing the immune system＇s ability to combat the disease. CAR T-cell therapy has shown remarkable success in some patients with otherwise challenging-to-treat blood cancers, leading to complete or partial remissions and offering new hope in the field of cancer treatment.
The major global suppliers of CAR T-Cell Therapy include Novartis, Gilead Sciences, Bristol-Myers Squibb, Johnson & Johnson, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), Autolus Therapeutics(Pipeline), Sorrento Therapeutics(Pipeline), Mustang Bio(Pipeline), Bluebird Bio(Pipeline), Cellectis(Pipeline), Allogene Therapeutics(Pipeline), Celyad(Pipeline), etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of CAR T-Cell Therapy. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global CAR T-Cell Therapy market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the CAR T-Cell Therapy market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of CAR T-Cell Therapy industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of CAR T-Cell Therapy Include:
Novartis
Gilead Sciences
Bristol-Myers Squibb
Johnson & Johnson
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
Autolus Therapeutics(Pipeline)
Sorrento Therapeutics(Pipeline)
Mustang Bio(Pipeline)
Bluebird Bio(Pipeline)
Cellectis(Pipeline)
Allogene Therapeutics(Pipeline)
Celyad(Pipeline)
CAR T-Cell Therapy Product Segment Include:
CD19 - Targeted
BCMA - Targeted
CAR T-Cell Therapy Product Application Include:
Lymphoma
Multiple Myeloma
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global CAR T-Cell Therapy Industry PESTEL Analysis
Chapter 3: Global CAR T-Cell Therapy Industry Porter's Five Forces Analysis
Chapter 4: Global CAR T-Cell Therapy Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global CAR T-Cell Therapy Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global CAR T-Cell Therapy Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, CAR T-Cell Therapy Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch＇s in-depth investigation and research, the global CAR T-Cell Therapy market size will reach 7,381.95 Million USD in 2025 and is projected to reach 34,749 Million USD by 2032, with a CAGR of 24.77% (2025-2032). Notably, the China CAR T-Cell Therapy market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
CAR T-cell therapy, or Chimeric Antigen Receptor T-cell therapy, is an innovative immunotherapy approach used to treat certain types of cancer, particularly blood cancers like leukemia and lymphoma. In CAR T-cell therapy, a patient＇s own T cells (a type of immune cell) are collected from their blood and then genetically engineered to express a chimeric antigen receptor (CAR) on their surface. This receptor is designed to recognize and target a specific protein found on the cancer cells. Once the CAR T cells are modified, they are multiplied in the laboratory and then infused back into the patient＇s bloodstream. These engineered T cells can now identify and attack cancer cells, effectively enhancing the immune system＇s ability to combat the disease. CAR T-cell therapy has shown remarkable success in some patients with otherwise challenging-to-treat blood cancers, leading to complete or partial remissions and offering new hope in the field of cancer treatment.
The major global suppliers of CAR T-Cell Therapy include Novartis, Gilead Sciences, Bristol-Myers Squibb, Johnson & Johnson, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), Autolus Therapeutics(Pipeline), Sorrento Therapeutics(Pipeline), Mustang Bio(Pipeline), Bluebird Bio(Pipeline), Cellectis(Pipeline), Allogene Therapeutics(Pipeline), Celyad(Pipeline), etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of CAR T-Cell Therapy. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global CAR T-Cell Therapy market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the CAR T-Cell Therapy market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of CAR T-Cell Therapy industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of CAR T-Cell Therapy Include:
Novartis
Gilead Sciences
Bristol-Myers Squibb
Johnson & Johnson
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
Autolus Therapeutics(Pipeline)
Sorrento Therapeutics(Pipeline)
Mustang Bio(Pipeline)
Bluebird Bio(Pipeline)
Cellectis(Pipeline)
Allogene Therapeutics(Pipeline)
Celyad(Pipeline)
CAR T-Cell Therapy Product Segment Include:
CD19 - Targeted
BCMA - Targeted
CAR T-Cell Therapy Product Application Include:
Lymphoma
Multiple Myeloma
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global CAR T-Cell Therapy Industry PESTEL Analysis
Chapter 3: Global CAR T-Cell Therapy Industry Porter's Five Forces Analysis
Chapter 4: Global CAR T-Cell Therapy Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global CAR T-Cell Therapy Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global CAR T-Cell Therapy Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, CAR T-Cell Therapy Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 CAR T-Cell Therapy Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 CAR T-Cell Therapy Product by Type
- 1.2.1 CD19 - Targeted
- 1.2.2 BCMA - Targeted
- 1.3 CAR T-Cell Therapy Product by Application
- 1.3.1 Lymphoma
- 1.3.2 Multiple Myeloma
- 1.4 Global CAR T-Cell Therapy Market Size Analysis (2020-2032)
- 1.5 CAR T-Cell Therapy Market Development Status and Trends
- 1.5.1 CAR T-Cell Therapy Industry Development Status Analysis
- 1.5.2 CAR T-Cell Therapy Industry Development Trends Analysis
- 2 CAR T-Cell Therapy Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 CAR T-Cell Therapy Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global CAR T-Cell Therapy Market Analysis by Country
- 4.1 Global CAR T-Cell Therapy Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global CAR T-Cell Therapy Revenue Analysis by Country (2020-2025)
- 4.1.2 Global CAR T-Cell Therapy Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.5 China CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.6 France CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.14 India CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global CAR T-Cell Therapy Market Revenue by Key Suppliers (2021-2025)
- 5.2 CAR T-Cell Therapy Competitive Landscape Analysis and Market Dynamic
- 5.2.1 CAR T-Cell Therapy Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 CAR T-Cell Therapy Market Analysis by Type
- 6.1 Global CAR T-Cell Therapy Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global CAR T-Cell Therapy Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Novartis
- 7.1.1 Novartis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Novartis CAR T-Cell Therapy Product Portfolio
- 7.1.3 Novartis CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 Gilead Sciences
- 7.2.1 Gilead Sciences Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Gilead Sciences CAR T-Cell Therapy Product Portfolio
- 7.2.3 Gilead Sciences CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 Bristol-Myers Squibb
- 7.3.1 Bristol-Myers Squibb Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Bristol-Myers Squibb CAR T-Cell Therapy Product Portfolio
- 7.3.3 Bristol-Myers Squibb CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 Johnson & Johnson
- 7.4.1 Johnson & Johnson Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 Johnson & Johnson CAR T-Cell Therapy Product Portfolio
- 7.4.3 Johnson & Johnson CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.5 JW Therapeutics
- 7.5.1 JW Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 JW Therapeutics CAR T-Cell Therapy Product Portfolio
- 7.5.3 JW Therapeutics CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.6 FOSUNKite
- 7.6.1 FOSUNKite Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 FOSUNKite CAR T-Cell Therapy Product Portfolio
- 7.6.3 FOSUNKite CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.7 CARsgen Therapeutics (Pipeline)
- 7.7.1 CARsgen Therapeutics (Pipeline) Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Product Portfolio
- 7.7.3 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.8 Autolus Therapeutics(Pipeline)
- 7.8.1 Autolus Therapeutics(Pipeline) Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
- 7.8.3 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.9 Sorrento Therapeutics(Pipeline)
- 7.9.1 Sorrento Therapeutics(Pipeline) Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.9.2 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
- 7.9.3 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.10 Mustang Bio(Pipeline)
- 7.10.1 Mustang Bio(Pipeline) Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.10.2 Mustang Bio(Pipeline) CAR T-Cell Therapy Product Portfolio
- 7.10.3 Mustang Bio(Pipeline) CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.11 Bluebird Bio(Pipeline)
- 7.11.1 Bluebird Bio(Pipeline) Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.11.2 Bluebird Bio(Pipeline) CAR T-Cell Therapy Product Portfolio
- 7.11.3 Bluebird Bio(Pipeline) CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.12 Cellectis(Pipeline)
- 7.12.1 Cellectis(Pipeline) Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.12.2 Cellectis(Pipeline) CAR T-Cell Therapy Product Portfolio
- 7.12.3 Cellectis(Pipeline) CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.13 Allogene Therapeutics(Pipeline)
- 7.13.1 Allogene Therapeutics(Pipeline) Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.13.2 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
- 7.13.3 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.14 Celyad(Pipeline)
- 7.14.1 Celyad(Pipeline) Basic Company Profile (Employees, Are
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
